Recently, small extracellular vesicles (sEVs) released by metastatic melanomas carrying PD‐L1 on their surface were reported to successfully suppress the function of CD8+ T cells,[15] which provided us with a rationale for developing FGL1 and PD‐L1 dual‐targeting sEVs as an anti‐rejection therapy. The gene discussed is CD8A; the disease is melanoma.